If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSosandar Regulatory News (SOS)

Share Price Information for Sosandar (SOS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12.00
Bid: 11.50
Ask: 12.50
Change: 0.00 (0.00%)
Spread: 1.00 (8.696%)
Open: 12.00
High: 12.00
Low: 12.00
Prev. Close: 12.00
SOS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Placing and Appointment of CEO

18 Dec 2006 07:00

Embargoed: 0700hrs, 18 December 2006

MeDaVinci plc ("MeDaVinci" or the "Company")

Group Strategy & Appointment of Rob Westerhof

MeDaVinci is pleased to announce its development as an active investment company focussed on innovative technologies, products and services in the Health and Wellness markets. The Company is delighted to appoint the former CEO of Philips Asia, Philips Medical Systems and Philips North America, Rob Westerhof, as Chief Executive of MeDaVinci (full details appear below) to spearhead the Company's strategy. Rob Westerhof will lead a team of experienced executive directors in identifying and assembling a group of portfolio companies in this sector, building from its current sole investment, ErgoDynamics Applications BV (19.2%), which has developed a proprietary and patented system for the prevention and relief of lower back pain.

It is envisaged that the type of investments that MeDaVinci will consider will include University spin-offs and the financing of inventions and entrepreneurs who have exciting products or concepts but the lack of capital or know-how to commercialise them. The Company will consider only those situations where it will be the (joint) lead investor and where it will place a MeDaVinci representative on the board of the portfolio company. Potential portfolio companies should display one or a number of the following characteristics: a distinctive or innovative market position, intellectual property or patents, niche expertise, a limited time to market (i.e. do not require extensive regulatory body approval) and a clear exit scenario. From his 35 years within the Philips organisation Rob Westerhof, along with the other executive directors, have access to a large number of opportunities that are considered initially too small or early-stage by the major medical companies but which, through access to growth capital, contacts and expert guidance, may be progressed to the level at which they become attractive acquisition targets, cash generators or suitable for IPO.

Placing

The Company has completed a Placing to raise gross funds of ‚£1,740,757 through the issue of 24,010,448 new ordinary shares. Of this ‚£1,000,000 has been subscribed for by Westlake Investments B.V., a company controlled by the newly appointed Chief Executive, Rob Westerhof. The funds will be added to the current cash reserves and are substantially for the implementation of the new investment strategy for which a number of potential specific investments are already under consideration. Application has been made for the 24,010,448 new ordinary shares, which will rank pari passu with existing ordinary shares, to be admitted to trading on AIM. Admission is expected to take place on 22 December 2006.

Details concerning appointment of Rob Westerhof

Full name: Robert Maarten Westerhof

Age: 63

Shareholding (post admission of Placing shares): 13,793,103 held through Westlake Investments B.V., representing 36.67% of the enlarged issued share capital.

Current Directorships: Getronics N.V.; Teleplan International N.V.; TTE Multi Media Ltd; Westlake Investments B.V.

Previous (five years) Directorships: PSV N.V; Philips North America Corporation; Philips Electronics China B.V.; Philips Hong Kong Ltd; AMSC Shanghai Ltd; SED Electronics Ltd; Hong Kong Science Park Ltd.

There are no matters requiring disclosure under paragraphs (g) (iii)-(viii) of Schedule Two of the AIM Rules.

For further information please contact,

Peter Teerlink, ChairmanMeDaVinci plcTel. +31 10 288 4343Ben SimonsHansard GroupTel. +44 (0)20 7245 1100

MEDAVINCI PLC
Date   Source Headline
16th Apr 20247:00 amRNSFull Year Trading Update
10th Jan 20247:00 amRNSTrading Update
15th Dec 20237:00 amRNSBoard Changes
12th Dec 20237:00 amRNSHalf Year Results
29th Nov 20237:00 amRNSNotice of Results and Investor Presentations
9th Nov 20237:00 amRNSMello Investor Presentation
18th Oct 20237:00 amRNSTrading & Strategic Update
13th Oct 20237:00 amRNSNotice of Trading Update
5th Oct 20232:25 pmRNSHolding(s) in Company
21st Sep 20231:02 pmRNSResult of AGM
25th Aug 20239:45 amRNSNotice of AGM and Posting of Annual Report
11th Jul 20237:00 amRNSFinal Results
4th Jul 20237:00 amRNSNotice of Results and Investor Presentation
17th Apr 20233:13 pmRNSHolding(s) in Company
13th Apr 20232:28 pmRNSHolding(s) in Company
12th Apr 20237:00 amRNSTrading Update & Progress on Growth Strategy
16th Mar 20237:00 amRNSAppointment of Interim Non-Executive Chairman
3rd Mar 20238:12 amRNSDirector/PDMR Dealing
17th Feb 20233:54 pmRNSResult of Retail Offer
17th Feb 20237:00 amRNSClose of Retail Offer
14th Feb 20232:51 pmRNSHolding(s) in Company
13th Feb 202311:55 amRNSHolding(s) in Company
8th Feb 20234:40 pmRNSSecond Price Monitoring Extn
8th Feb 20234:35 pmRNSPrice Monitoring Extension
8th Feb 20231:30 pmRNSResult of Placing
8th Feb 20239:16 amRNSRetail Offer
8th Feb 20237:00 amRNSProposed Placing to raise a minimum of £4 million
6th Feb 20237:00 amRNSDeath of Director
23rd Jan 20237:00 amRNSNew Third Party Arrangement
10th Jan 20237:00 amRNSTrading Update
13th Dec 20227:00 amRNSHalf Year Results
17th Nov 20227:00 amRNSNotice of Results and Investor Presentation
15th Nov 20225:25 pmRNSAIM Rule 17 Schedule 2(g) Update
18th Oct 20227:00 amRNSHalf Year Trading Update
15th Sep 20223:24 pmRNSResult of AGM & Notice of Trading Update
22nd Aug 20227:00 amRNSNotice of AGM and Posting of Annual Report
18th Aug 20227:00 amRNSBoard Changes and Change of Auditor
12th Jul 20227:00 amRNSFinal Results
24th Jun 20227:00 amRNSNotice of Results and Investor Presentation
10th Jun 20223:31 pmRNSDirector/PDMR Shareholding
6th May 202212:55 pmRNSDirector/PDMR Dealing
14th Apr 20227:00 amRNSBoard Appointment
6th Apr 20222:05 pmRNSSecond Price Monitoring Extn
6th Apr 20222:00 pmRNSPrice Monitoring Extension
6th Apr 20227:00 amRNSTrading Update and New Third Party Arrangements
6th Jan 20227:00 amRNSTrading Update
20th Dec 20219:00 amRNSExercise of Warrants and Total Voting Rights
30th Nov 20217:00 amRNSHalf Year Results
12th Nov 20217:00 amRNSNotice of Results
7th Oct 202111:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.